MVI welcomes positive opinion by European regulators on GSK’s Mosquirix™ (RTS,S)

Read more »

Raising Air-Conditioned Mosquitoes to Stop Malaria

Read more »

Bowl of vials

Photo credit: PATH / Gabe Bienczycki

Partnering with us

PuzzleWe are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.

Our portfolio

MVI portfolioWe maintain a diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.

View the portfolio »Subscription button

What we do and how we do it

MVI overview imageWe identify potentially promising malaria vaccine approaches and systematically move them through the development process. At the same time, we work to catalyze access to a successful malaria vaccine in the countries that need it most.

Read more »

News and announcements

RTS,S modeling study published in The Lancet

Modelers predict the RTS,S malaria vaccine candidate could have significant public health impact and high cost-effectiveness across a range of sub-Saharan African settings.


WHO advisory group recommendation on use of RTS,S malaria vaccine candidate

GSK and PATH await final policy recommendation by the end of 2015.


Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine

Read a newly published article and accompanying editorial in The New England Journal of Medicine.


RTS,S malaria vaccine Candidate receives positive scientific opinion from EMA

The European Medicines Agency’s (EMA's) Committee for Medicinal Products for Human Use has adopted a positive scientific opinion for Mosquirix™ (RTS,S), for use outside the European Union.


A first: European regulators give thumbs up to malaria candidate vaccine

On the PATH blog, Dr. David C. Kaslow discusses the latest news and next steps for the RTS,S malaria vaccine candidate.

Events and Conferences

ASTMH 64th Annual Meeting
October 25–29, 2015